AstraZeneca PLC — Board/Management Information 2013

Jan 15, 2013

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5876V

AstraZeneca PLC

15 January 2013

ASTRAZENECA ANNOUNCES CHANGES TO SENIOR MANAGEMENT TEAM

AstraZeneca today unveiled changes to its executive leadership team. The new, expanded membership of AstraZeneca's Senior Executive Team, which comes into effect immediately, includes increased representation of the company's scientific expertise, key products and key markets.

The changes include the creation of:

·     Three senior research and development roles responsible for discovery and early stage development in small molecules; discovery and early stage development in biologics; and late stage development.

·     Three roles representing the commercial regions: North America, Europe and International.

·     A role responsible for global portfolio and product strategy, bridging between the R&D and sales organisation.

As a result of the changes, two senior roles - President of Research and Development, held by Martin Mackay, and Executive Vice President, Global Commercial, held by Tony Zook - have been eliminated. Martin Mackay and Tony Zook will leave the company at the end of January.

The full Senior Executive Team is as follows:

Pascal Soriot              Chief Executive Officer and Executive Director

Simon Lowth              Chief Financial Officer and Executive Director

Mene Pangalos           Executive Vice President, Innovative Medicines

Bahija Jallal                 Executive Vice President, MedImmune

Briggs Morrison          Executive Vice President, Global Medicines Development

Paul Hudson               Executive Vice President, North America

Ruud Dobber              Executive Vice President, Europe

Mark Mallon                 Executive Vice President, International

David Smith                Executive Vice President, Operations & IS

Lynn Tetrault               Executive Vice President, Human Resources & Corporate Affairs

Katarina Ageborg        Chief Compliance Officer

Jeff Pott                      General Counsel

The appointment of Executive Vice President, Global Portfolio & Product Strategy will be made at a later date.

Pascal Soriot, Chief Executive Officer, said: "This new senior executive team structure, that draws heavily from the leadership talent within the company, enables us to bring an even sharper management focus to key pipeline assets, key brands and key markets, and helps us further accelerate decision-making."

Commenting on Martin Mackay and Tony Zook, Pascal Soriot said: "I would like to thank Martin and Tony for their contribution and the exemplary leadership they have shown in their time at AstraZeneca. We wish them well in their future endeavours."

Details of AstraZeneca's Senior Executive Team, including biographies, can be found on the company's web site at www.astrazeneca.com/About-Us/Board-and-management

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

Media Enquiries UK

Esra Erkal-Paler                     +44 207 604 8030

Vanessa Rhodes                    +44 20 7604 8037

Media Enquiries Sweden

Ann-Leena Mikiver                +46 8 553 260 20

Investor Enquiries
James Ward-Lilley Karl Hård	+44 207 604 8122 +44 20 7604 8123	mob: +44 7785 432613 mob: +44 7789 654364
Nicklas Westerholm	+44 20 7604 8124	mob: +44 7585 404950
Ed Seage	+1 302 886 4065	mob: +1 302 373 1361
Colleen Proctor	+1 302 886 1842	mob: +1 302 357  4882

15 January 2013

- ENDS -

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCZMGMMZKKGFZM